Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.00766 USD | +7.89% | -26.67% | -65.00% |
Feb. 22 | Baudax Bio, Inc. Filed for Bankruptcy | CI |
2023 | Baudax Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Business Summary
Number of employees: 9
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Innovative Products for Hospital and Other Acute Care Settings
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +17.50% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 1 | 100.0 % | 1 | 100.0 % | +17.50% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Gerri Henwood
CEO | Chief Executive Officer | 71 | 18-12-31 |
Natalie McAndrew
DFI | Director of Finance/CFO | 50 | 23-10-08 |
Diane Myers
PRN | Corporate Officer/Principal | 60 | 19-10-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 83 | 19-11-20 | |
Gerri Henwood
CEO | Chief Executive Officer | 71 | 18-12-31 |
Wayne Weisman
CHM | Chairman | 68 | 19-11-20 |
Andrew Drechsler
BRD | Director/Board Member | 52 | 20-08-19 |
William Ashton
BRD | Director/Board Member | 73 | 19-11-20 |
Arnold Baskies
BRD | Director/Board Member | 74 | 20-08-19 |
Yong-Chan Kim
BRD | Director/Board Member | 50 | 23-07-02 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 43,593,082 | 43,585,476 ( 99.98 %) | 0 | 99.98 % |
Stock B | 0 | 36,267 | 0 | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-67.73% | 372K | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+43.45% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- BXRXQ Stock
- Company Baudax Bio, Inc.